41. 巨細胞性動脈炎 Giant cell arteritis Clinical trials / Disease details

臨床試験数 : 128 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 124

diseases per page:

Showing 1 to 10 of 128 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002528-18-DK (EUCTR)	22/02/2022	30/07/2021	RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insuffi ...	RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insuffi ...	Glucocorticoid-induced adrenal insufficiency MedDRA version: 20.0;Level: LLT;Classification code 100 ...	Trade Name: Hydrokortison orion Product Name: hydrokortison Product Code: H02AB09 INN or Proposed INN: h ...	Copenhagen University Hospital Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	325	Phase 4	Denmark
2	EUCTR2020-004809-31-DK (EUCTR)	18/11/2021	01/08/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Australia;Denmark;S ...
3	EUCTR2020-004809-31-NO (EUCTR)	16/11/2021	28/06/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe Product Name: Cosentyx Product ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...
4	EUCTR2020-004809-31-BG (EUCTR)	08/11/2021	26/08/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUM ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...
5	EUCTR2020-004809-31-DE (EUCTR)	19/10/2021	12/07/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...
6	EUCTR2020-004809-31-PT (EUCTR)	13/10/2021	07/07/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx Product Name: Cosentyx Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Trade ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...
7	NCT04930094 (ClinicalTrials.gov)	October 6, 2021	15/6/2021	Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorti ...	A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Invest ...	Giant Cell Arteritis (GCA)	Biological: Secukinumab 300 mg;Other: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	50 Years	N/A	All	240	Phase 3	United States;Australia;Belgium;Finland;France;Germany;Hungary;Poland;Portugal;Spain;Switzerland;Tur ...
8	EUCTR2020-004809-31-FI (EUCTR)	05/10/2021	16/07/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...
9	EUCTR2020-004809-31-FR (EUCTR)	24/09/2021	22/06/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx Product Name: Cosentyx Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Trade ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...
10	EUCTR2020-004809-31-IT (EUCTR)	16/09/2021	22/10/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to inves ...	Giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Prednisone Product Name: Prednisone Product Code: [-] INN or Proposed INN: PREDNISONE Trade ...	NOVARTIS PHARMA AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;South Afr ...

First Previous1 2 3 4 5…13Next Last